JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / Cells / Cell Lines

Anti-BCMA CAR Jurkat/NFAT (Luciferase) Reporter Cell Line

SKU : BHC18200203

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

BPS Bioscience

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	79694
Description	The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a stable cell line made from the anti-BCMA scFV CAR lentivirus (Biohippo #79701). It has been validated for anti BCMA-CAR expression by FACS, and for functional activation stimulated by both soluble BCMA protein (Biohippo #79467) and BCMA/CHO target cells (Biohippo #79500). Mycoplasma testing: The cell line has been screened using the PCR-based VenorGeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species. Host Species: human Supplied as Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO and 90% FBS
Background	The development of CAR-T cells is a complex process that requires I) screening and sequencing of mAbs that are specific to the cancer antigens; II) synthesis of scFv cDNA and clone into Chimeric Antigen Receptor (CAR) cassette in Lentivector (e.g. anti-BCMA scFv in 3rd generation CAR cassette in lentivector); III) packaging and production of high titer lentivirus CAR encoding lentivirus; IV) isolation, activation and expansion of patient-derived T cells that exhibit a specific cellular phenotype (e.g. CD4+ or CD8+ or a mix); V) and transduction of activated T cells with CAR-encoding lentivirus; VI) Validation of engineered CAR-T cells through FACS and functional analysis. Biohippo has developed an anti-BCMA CAR Jurkat/NFAT-luciferase stable reporter cell line, it is one of a series of reporter bioassays using CAR-T Lentivirus and Jurkat/NFAT-luciferase reporter cell lines. The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a great system to predict the mechanism of action (MOA) and therapeutic potential of the anti-BCMA CAR lentivirus before using it with patient-derived primary T cells. It is a single cell clonal stable cell line developed by transducing the Jurkat/NFAT-Luciferase reporter cells with the anti-BCMA scFV CAR lentivirus (Biohippo #79701).
Application	Predict the MOA of the CAR design Measurements of antibody (scFV-CAR) specificity Screen and validate BCMA-expressing caner target cells
Host Cell	Jurkat
Synonyms	tumor necrosis factor receptor superfamily member 17, B-Cell Maturation Antigen, TNFRSF17, CD28, T-cell receptor zeta, 4-1BB, CD137
Shipping Temperature	-80°C (dry ice)
Note	License DisclosurePurchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc.

Storage Stability	Immediately upon receipt, store in liquid nitrogen.

Reference	1. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Wang et. al. J Hematol Oncol. 2019 Jun 11;12(1):59 2. Chimeric antigen receptor T cell therapy for multiple myeloma. Hasegawa et.al. Inflamm Regen. 2019 Jun 4;39:10. 3. Novel targets for the treatment of relapsing multiple myeloma. Giuliani et. al. Expert Rev Hematol. 2019 Jun 3:1-16. 4. Anti-BCMA antibodies in the future management of multiple myeloma. Gavriatopoulou et. al. Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326.

Product Manual	Datasheet

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHC18200203	79694	2 vials	$10340		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.